Literature DB >> 19745503

Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey.

Suzan Sacar1, Sibel Kabukcu Hacioglu, Ali Keskin, Huseyin Turgut.   

Abstract

BACKGROUND: Infectious complications in febrile neutropenic patients are still major causes of morbidity and mortality despite significant advances in diagnostic techniques and antimicrobial therapy. In this study, we describe the characteristics of patients with hematological malignancies who were evaluated for suspected infection. This study was also conducted to assess the isolation rate of bacterial and fungal causative agents in febrile neutropenic attacks.
METHOD: The study was conducted at Pamukkale University Hospital, Turkey. In order to identify the characteristics of patients with hematological malignancies in the presence/suspicion of any accompanying infectious disease, patients' charts with hematological malignancies were reviewed for signs/symptoms of any infection between October 1, 2001, and May 31, 2005, retrospectively.
RESULTS: Overall, 90 infectious episodes occurred in 59 patients. The most common underlying diseases were acute myelogenous leukemia (61.0%) and acute lymphocytic leukemia (15.3%). The absolute neutrophil count was lower than 100/mm(3) in 33 (36.7%) episodes. Microbiologically and clinically documented infections and fever of unknown origin were observed in 35.6%, 28.9%, and 35.6% of the participants, respectively. Bloodstream infections and pneumonia were detected in 21.1% and 18.9% of episodes, respectively. Gram negative organisms were most common (58.4%), followed by gram positive cocci. A combination of third generation cephalosporin and an aminoglycoside were used in 44.4% of episodes initially. Fever resolved in 24.4% of episodes using the initial therapy. The mortality rate was 15.6%.
CONCLUSION: These results showed that infections with gram-negative bacteria continue to predominate in febrile neutopenic episodes in our center.

Entities:  

Mesh:

Year:  2008        PMID: 19745503     DOI: 10.3855/jidc.197

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

1.  Response of first-line antibiotic therapy in patients with febrile neutropenia during treatment of hematological disorders.

Authors:  M Taj; R N Qureshi; T Farzana; T S Shamsi; S S Ahmed
Journal:  Indian J Hematol Blood Transfus       Date:  2014-09-12       Impact factor: 0.900

2.  Pattern of Antimicrobial Sensitivity in Microbiologically Documented Infections in Neutropenic Patients with Haematological Malignancies: A single Center Study.

Authors:  Aisha Jamal; Naveena Fatima; Sajjad Shaikh; Bushra Kaleem; Qurratul Ain Rizvi; Uzma Zaidi; Munira Borhany; Tahir Shamsi
Journal:  Indian J Microbiol       Date:  2019-03-04       Impact factor: 2.461

3.  Clinical and Microbiological Profile of Pathogens in Febrile Neutropenia in Hematological Malignancies: A Single Center Prospective Analysis.

Authors:  M Taj; T Farzana; T Shah; S Maqsood; S S Ahmed; T S Shamsi
Journal:  J Oncol       Date:  2015-07-28       Impact factor: 4.375

4.  Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting.

Authors:  Ali Hakan Kaya; Emre Tekgündüz; Fazilet Duygu; Dicle Koca; Filiz Bekdemir; Hikmetullah Batgi; Bahar Ulu Uncu; Tuğçe Nur Yiğenoğlu; Mehmet Sinan Dal; Merih Çakar Kızıl; Fevzi Altuntaş
Journal:  Balkan Med J       Date:  2017-04-05       Impact factor: 2.021

5.  Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients.

Authors:  Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör
Journal:  Turk Pediatri Ars       Date:  2017-12-01

6.  A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period.

Authors:  Roberto L Parodi; Mariana Lagrutta; Mauro Tortolo; Estefanía Navall; María S Rodríguez; Gervasio F Sasia; Lucas F De Candia; Matias A Gruvman; Oscar Bottasso; Alcides A Greca
Journal:  PLoS One       Date:  2019-10-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.